Denver, CO – Researchers have shown that the drug benralizumab is as effective and safe as mepolizumab for inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) according to a study published today in The New England Journal of Medicine. The results of the non-inferiority study were presented at...
treatment News
SANTA ANA, Calif. — NKGen Biotech Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has received a No Objection Letter (“NOL”) from Health Canada for its Clinical Trial Application (“CTA”) for a Phase...
SANTA ANA, Calif. — NKGen Biotech, Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced the dosing of the first patient in its Phase 1/2a trial evaluating SNK01, a cryopreserved autologous, non-genetically modified NK cell therapy...
STANS, Switzerland – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces new study data which support the mechanism of action for mazindol, the active...
STANS, Switzerland – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into a License Agreement (the “Agreement”) with Novartis Pharma...
An experimental stem-cell treatment developed by StemCells of Palo Alto has shown no dangerous side effects after being injected into six children with a rare and as-yet always fatal brain disorder, the company said Monday. The groundbreaking study begun in 2006 involves children suffering from Batten disease, a heretofore incurable...
Nivolumab with or without ipilimumab as maintenance therapy after first-line chemotherapy failed to prolong survival among patients with extensive-disease small cell lung cancer (ED-SCLC), according to the results of the CheckMate 451 trial published in the Journal of Clinical Oncology. Although most patients with ED-SCLC respond to first-line chemotherapy, recurrence is...
BOSTON, Mass. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood...
EVANSTON, Ill. — Researchers led by Northwestern University and Washington University School of Medicine in St. Louis have developed a new, first-of-its-kind sticker that enables clinicians to monitor the health of patients’ organs and deep tissues with a simple ultrasound device. When attached to an organ, the soft, tiny sticker...
Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s...